PMV Pharmaceuticals (PMVP) stock

Market cap $71.1M

$1.75

+4.79%

Market closed. Prices as of Thursday's close.

Quality Score

Average

In its industry

#46of 276

Biotech

Checks firing

7of 14

Trending up

From 52-week high

-8.4%

Above the 200-day

NextQ1 2027“…platinum-resistant/refractory ovarian cancer patients with a TP53 Y220C mutation in the first quarter of 2027…”Filing with regulators · 8-K, Aug 14

Cash$79.4M, about 4 quarters at the last year's spendingOn Jun 30 · raised money since, not counted · the company says “through second quarter of 2027”

Follow PMVP's trial news. Pro members can get an alert when PMV Pharmaceuticals files news, and see its trials, share raises, and its CEO's filings.

Get an optional alert when PMVP files news on its trialsFree for 24 hours. No account needed.

Cash$79.4M, about 4 quarters at the last year's spendingOn Jun 30 · raised money since, not counted · the company says “through second quarter of 2027”

Pipeline and cash

What's next for PMVP, and how long its cash lasts

From PMV Pharmaceuticals’s SEC filings and ClinicalTrials.gov: the company’s own words, the registry’s dates, and arithmetic, not a forecast. Companies often miss their own dates.

Next step the company has named

Q1 2027“…submitting an NDA for accelerated approval of rezatapopt as a treatment for platinum-resistant/refractory ovarian cancer patients with a TP53 Y220C mutation in the first quarter of 2027.”Filing with regulators · 8-K, Aug 14

What it means: a filing asks regulators to approve a drug for sale. Once it is complete and accepted, the FDA sets a decision date, and we show it here.

Lead program: Rezatapopt · TP53 Y220C Mutation · Phase 1
Its trial: Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.Phase 1 · Recruiting · 14 people · main data estimated Mar 2027 · NCT07372625

1 more trial, 1 with data due this year, 22 filings, for Pro members.

Cash runway Jun 30 balance sheet

About 4 quarters

$79.4M in cash and short-term investments, at its spending over the last year

What it means: how long the cash would last at the same pace, before any new money. The company's own estimate is “through second quarter of 2027” (8-K, Aug 14). It has raised money since that balance sheet, which is not counted here.

For Pro members: the cash used each quarter, and the math.

Dilution on the horizon

Shelf registration (S-3, filed Nov 20, 2024)
At-the-market share sales program (424B3, filed Nov 27, 2024)

A shelf lets a company sell shares later; an at-the-market program sells them into the market over time. Neither is a sale by itself.

For Pro members: 2 raises and their amounts, and the share count against a year ago.

Insiders

No open-market buys or sales by its officers or directors in their filings of the last year.

From their own Form 4 filings: buys and sales in the market, not awards or shares withheld for tax.

Get an optional alert when David Mack buys or sells

For Pro members: every trade, and David Mack’s 10 filings and quotes.

Get an optional alert when PMVP files news on its trialsFree for 24 hours. No account needed.

See every upcoming FDA date →

Biotech dates

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their own filings, soonest first and small companies first.

DateStockDrug

In 28 daysFDA decisionIn 28 days · FDA decisionINOInovio PharmaceuticalsINO-3107INOInovio Pharmaceuticals · $122MINO-3107Under FDA review
In 39 daysANDA decisionIn 39 days · ANDA decisionNRXPNRX PharmaceuticalsDrug not namedNRXPNRX Pharmaceuticals · $130MDrug not namedA generic, under FDA review
In 51 daysFDA decisionIn 51 days · FDA decisionCAPRCapricor TherapeuticsDrug not namedCAPRCapricor Therapeutics · $486MDrug not namedUnder FDA review

8 more FDA dates and 107 trial data dates in the next 60 days. Pro members see every one, with the cash against its date and an optional alert before it. Get in free →

Why PMVP is up

PMV Pharmaceuticals rose 31.1% over the five sessions to Oct 1.

Biotech stocks fell a median 3.4% and the S&P 500 fell 0.4% in those sessions; PMV Pharmaceuticals rose 31.1%.

Sources: Price history, Oct 1, 2026

1 more driver and the timeline, for Pro members

Quality Score

Why PMVP scores 7

AverageTrending up, 7 of 14 checks firingWhat the Quality Score means

Poor is below 0. Average starts at 6, Above Average at 11, Excellent at 15, and Exceptional at 20.

Well above its own recent run. PMVP scores 7 today, against a median of 1.5 over its last 20 recorded sessions.

+7Chart checks 7 of 14 firing right now, one point each
+3Long-term trend above a rising 200-⁠day average, near its 52-⁠week high

Run-up adds
Size subtracts
Profit subtractsRead on the last four quarters against the four before, or the last full year where no quarters are filed.
Volatility subtractsA daily range of 5% or more with nothing behind it (no profit or cash flow, sales shrinking, or 10% more shares outstanding with no free cash flow): -1, or -2 from 8%.
Cash flow subtracts-1 when free cash flow over the last four quarters is negative.

No effect today: Growth, Dilution, Persistence, and News.

What every line is worth, and the reason behind it, on PMVP and every other stock.Get in free →

Price, score, chart checks, and the industry rank are from a snapshot taken at 1:06 AM ET, at least 15 minutes behind. How we rank stocks.

What's next

Expected to report Mon Nov 16, before the open

After its last 4 reports it closed +5.0% on average, higher 4 of 4 times.

What would move PMVP's score: 7 things, for Pro members

Alert me when PMVP's Quality Score turns up

Free for 24 hours. No account needed. Then keep going with a free account.

Pro

Here is what Pro members see.

Every stock gets a card like this one, and a page with its price in real time, every line of its score, the chart, and its filings.

A Pro member's scanner card for AMD: the Quality Score badge, the rank in the scan and in its industry, the chart checks bar, three plain lines on its strength, notable holders, and early signs, and pills for size, volume, RSI, and short interest — A card on the scanner, shown on AMD

A Pro member's stock page for AMD: the Quality Score with its rank, the checks firing, and the reason behind it, the live price, and the chart — A stock page

The scanner a Pro member sees: every stock as a card with its Quality Score, rank, and chart checks bar, and the watchlist — The scanner

The 14 checks

PMVP has 7 of 14 checks firing

One per group is shown here.

Trend1 of 5 shown

MA FAN 21 EMA W.EMA HH/HL 52W HI

Averages stacked in order, price near its high.

Volume1 of 3 shown

VOL VDU U/D VOL

Heavy volume on the run, quiet volume at rest.

Tight range1 of 3 shown

ATR SQZ SQUEEZE NR7

The daily range is tight against its own recent history.

Buying1 of 3 shown

OBV+CLOSE HI SPRING

Closes near the high, and buyers step in on dips.

The other 10 checks on PMVP, and all 14 on every stock.Get in free →

Also on the chart

Not scored

Shown for reference. None of these counts toward the Quality Score: in our tests on 20 years of daily prices, none of them improved it.

RSI 1471.5
70 or above.
MACD (12, 26, 9)Above signal
Crossed above its signal line 1 session ago.
50-day average$1.31
The price is 33.6% above it.
200-day average$1.28
The price is 36.7% above it. The 50-day is above the 200-day, since Sep 16.
ADX 1418.9
Under 25, with +DI above -DI.
Support$1.36
Swing low from May 1, 22.3% below the price.
Resistance$1.88
Swing high from Mar 2, 7.4% above the price.
Bollinger Bands (20, 2)Above
The bands run from $1.19 to $1.66.
Volume2.2x
Against its 20-day average, for the time of day.

Its industry

How PMVP ranks in Biotech

PMVP is #46 of 276 by Quality Score. The top three are shown with their scores, and more by name.

1KNSAKiniksa Pharmaceuticals International7/1418
2ABCLAbCellera Biologics6/1416
3OABIOmniAb9/1415
PHATPhathom PharmaceuticalsOpen for its score
PLXProtalix BioTherapeuticsOpen for its score
PRAXPraxis Precision MedicinesOpen for its score
PROKProKidneyOpen for its score
46PMVPPMV Pharmaceuticals7/147

When does PMVP report earnings, and what happens after?

Expected to report Mon Nov 16, before the open (in 45 days). Not yet confirmed by the company.

+6.8%+7.2%+2.2%+3.7%

Nov 12Mar 6May 12Aug 14

Reported	When	Gap	Reaction	5 sessions
Aug 14, 2026Before open	Before open	+1.2%	+3.7%	+7.0%
May 12, 2026Before open	Before open	+3.6%	+2.2%	-10.1%
Mar 6, 2026Before open	Before open	+6.5%	+7.2%	+3.3%
Nov 12, 2025Before open	Before open	+1.5%	+6.8%	+5.3%

The gap is the next open against the close before the report; the reaction is where that session closed. PMVP closed higher after 4 of its last 4. Past behavior, not a forecast.

Report dates and past reactions come from sessions that have already closed, so none of these figures move.

The company

About PMV Pharmaceuticals

PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. The key product candidate, rezatapopt, is designed to be an orally available small molecule that structurally corrects the mutant p53 protein with the Y220C mutation. Currently, the product candidates are undergoing preclinical and clinical testing, and company relies on third parties for the manufacture after marketing approvals.

54 employeesPrinceton, NJpmvpharma.com

Pro

Every line of the score, on every stock.

Real-time prices, no delay
Every line of PMVP's score, with the points and the reason
All 14 checks on PMVP and on all 2,958 stocks
Every stock ranked, with the chart
Every filing, and optional alerts on PMVP

See all 14 checks on PMVPFree for 24 hours. No account needed. Then keep going with a free account.

Questions

Straight Answers.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, trial included, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.

Where does the data come from?

Daily bars, quotes, reference data, headlines, and short interest come from Massive, formerly Polygon, a licensed market data vendor. The age of the quotes is shown at the top of every page. Insider trades, notable holders and profits come straight from the SEC. That means Form 4 filings, 13F filings and XBRL financial data on EDGAR. Government filings come from the public STOCK Act and Office of Government Ethics disclosures. The market-wide headlines on the market line also come from the public headline feeds CNBC, MarketWatch and Yahoo Finance publish, shown as the headline, the source and a link to the article. Splits, dividends, and the financial statements on each ticker page come from the vendor's reference data. The 8-K filings on EDGAR are read for the items that move a price. Five years of history is loaded for every stock. So the 200-day and 52-week checks rest on real history. Options flow is not part of the product.

Do I need an account?

Not for the first 24 hours. Tap any green button and you're in, with no email and no password. To keep going, create a free account with Google, Apple, or your email. There is no password to make up.

Is this investment advice?

No. It is a screening tool that scores stocks on the chart, the company's own results, and the news and filings. It does not know your situation and it is not a recommendation to buy or sell anything. Please do your own research.

The price, the score, the chart checks and readings, and the industry rank on this page are delayed at least 15 minutes. Filings are shown as filed, because a disclosure is already days or weeks old when it becomes public. Earnings dates and past reactions are settled sessions.